Pseudomonas infection

Summary

Pseudomonas infection (MONDO:0005141) is a disease and 15 clinical trials. Top therapeutic interventions include ceftobiprole medocaril free acid, fosfomycin tromethamine, and tobramycin. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Pseudomonas infection
Mondo ID	MONDO:0005141
EFO	EFO:0001076
MeSH	D011552
SNOMED CT	63398001
UMLS	C0033817
MedGen	10993
Is cancer (heuristic)	no

Also known as: Pseudomonas caused disease or disorder · Pseudomonas disease or disorder · Pseudomonas infectious disease

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › Pseudomonas infection

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (1): Pseudomonas aeruginosa infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Piperacillin	Phase 3 (in late-stage trials)
Tazobactam	Phase 3 (in late-stage trials)
Tobramycin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE3	3
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT00634192	PHASE3	COMPLETED	Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
NCT03715322	PHASE3	UNKNOWN	Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
NCT00610623	PHASE2	TERMINATED	Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia
NCT03638830	PHASE2	COMPLETED	Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
NCT00910351	PHASE1	COMPLETED	Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
NCT02178254	PHASE1	COMPLETED	Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
NCT03044223	Not specified	RECRUITING	Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
NCT06738771	Not specified	RECRUITING	Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
NCT07056881	Not specified	RECRUITING	Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa
NCT00014950	Not specified	COMPLETED	Benefits and Risks of Newborn Screening for Cystic Fibrosis
NCT00027183	Not specified	COMPLETED	Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
NCT00235690	Not specified	COMPLETED	Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)
NCT00621803	Not specified	TERMINATED	Lcr35 / ICU / P. Aeruginosa
NCT03510351	Not specified	COMPLETED	Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEFTOBIPROLE MEDOCARIL FREE ACID	4	2
FOSFOMYCIN TROMETHAMINE	4	1
TOBRAMYCIN	4	1
FOSFOMYCIN SODIUM	3	1
CHEMBL6175829	0	1
CHEMBL4299381	0	1